Clinical Trial Update: 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia [Phase 3]

View source ↗

Summary

Phase 3, six-month study evaluating eszopiclone for primary insomnia has completed. The snippet does not include trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Lunesta (eszopiclone)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Primary Insomnia | Phase 3 | Status: COMPLETED